David Meeker, Rhythm Pharmaceuticals CEO
July 20, 2020 08:47 AM EDT
People
R&D

Ex-Sanofi Gen­zyme chief David Meek­er hops to a new biotech CEO post, this time fo­cus­ing on quick leap to com­mer­cial­iza­tion

John Carroll

Editor & Founder

Six months af­ter Rhythm Phar­ma­ceu­ti­cals CEO Kei­th Gottes­di­ener an­nounced plans to ex­it on the heels of the biotech’s first FDA fil­ing, the Boston-based biotech …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

As­traZeneca CEO reaf­firms com­mit­ment to Chi­na fol­low­ing ex­ec­u­tive's de­ten­tion

Mer­ck, As­traZeneca tout Phase 3 win for can­cer-turned-rare dis­ease drug

Sanofi, Ope­nAI, For­ma­tion Bio de­but pa­tient re­cruit­ing tool, will use in Phase 3 mul­ti­ple scle­ro­sis stud­ies

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times